drugset / Trial / NCT04814446

Nonavalent HPV Vaccine in the Treatment of Difficult-to-treat Palmo-plantar Warts

NCT04814446 ↗

Phase 3 Unknown 146 enrolled Assistance Publique - Hôpitaux de Paris
RandomizedParallel-groupDouble-blindTreatment

Summary

Cutaneous viral warts are very common and are caused by the human papilloma virus (HPV). Most people experience warts in one form or another at some point in their lives. Cutaneous warts are related to different types of HPV. For the palms and soles, HPV 2 has been the most frequently found but HPV 1, 4, 27, and 57 have also been described. Our hypothesis is that vaccination by nonavalent vaccine against HPV could lead to a complete resolution of difficult-to-treat palmo-plantar warts patients of more than 15 years and 3 months of age.

Timeline

Start
2022-06-29
Primary completion
2025-06-29
Completion
2026-06-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Vaccination Vaccine 0.5 ml Intramuscular

Indications